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Introduction
Small nuclear RNPs (snRNPs) are core components of spliceo-
somes and are required for the catalytic steps of splicing. Most 
spliceosomal snRNPs, with the exception of U6, contain a com-
mon set of Sm proteins that associate with the Sm site of the 
small nuclear RNA (snRNA; Matera et al., 2007). The biogene-
sis of Sm-class snRNPs is a highly orchestrated process that 
takes place in multiple cellular compartments (Matera and 
Shpargel, 2006). Subsequent to transcription and nuclear export 
of the snRNA, the survival of motor neurons (SMN) complex 
mediates the assembly of snRNPs by loading Sm proteins onto 
the snRNA (Meister et al., 2002; Paushkin et al., 2002). The 
core factor within this large oligomeric complex is the SMN 
protein (Meister et al., 2002; Paushkin et al., 2002). Importantly, 
mutations that reduce the level of SMN protein result in the in-
herited human neuromuscular disorder spinal muscular atrophy 
(Lefebvre et al., 1995). The molecular etiology of spinal muscu-
lar atrophy is currently unknown. Recent work suggests that the 
perturbation of snRNP biogenesis may be a contributing factor 
(Winkler et al., 2005). However, these fi  ndings do not rule out 
tissue-specifi  c functions of SMN as factors contributing to the 
disease pathology (Briese et al., 2005; Eggert et al., 2006; 
Rajendra et al., 2007).
Three of the seven Sm proteins, B/B′, D1, and D3, contain 
symmetric dimethylarginine (sDMA) modifi  cations within their 
C-terminal tails (Brahms et al., 2000, 2001). This posttrans  lational 
modifi  cation is catalyzed by type II protein arginine methyl-
transferases (PRMTs; for review see Bedford and Richard, 
2005). Type I enzymes catalyze the more common asymmetric 
dimethylarginine (aDMA) modifi  cation. PRMT5 and PRMT7 
have each been shown to possess type II methyltransferase 
activity and to symmetrically dimethylate Sm proteins in vitro 
(Branscombe et al., 2001; Rho et al., 2001; Lee et al., 2005). 
Reduction of PRMT5 levels using RNAi correlates with a de-
crease in the level of Sm protein sDMA modifi  cation (Boisvert 
et al., 2002). Furthermore, in cytoplasmic lysates, PRMT5 is 
found in a complex with MEP50/WD45, iCln, and Sm proteins 
(Friesen et al., 2001b, 2002; Meister et al., 2001). PRMT7 was 
identifi  ed more recently as a type II methyltransferase (Lee 
et al., 2005). Consequently, very little is known about this enzyme.
The precise role of Sm protein sDMA modifi  cation in 
snRNP biogenesis remains unclear. Recruitment of Sm proteins 
to the SMN complex is thought to be facilitated by sDMA mod-
ifi  cation. Consistent with this notion, SMN binds with a much 
higher affi  nity to sDMA-modifi  ed Sm proteins (Brahms et al., 
2001; Friesen et al., 2001a). However, a loss of function muta-
tion in dart5, the fl  y orthologue of PRMT5, is homozygous 
  viable (Gonsalvez et al., 2006). The mutants displayed no overt 
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mall nuclear ribonucleoproteins (snRNPs) are core 
components of the spliceosome. The U1, U2, U4, 
and U5 snRNPs each contain a common set of 
seven Sm proteins. Three of these Sm proteins are post-
translationally modiﬁ  ed to contain symmetric dimethyl-
arginine (sDMA) residues within their C-terminal tails. 
However, the precise function of this modiﬁ  cation in the 
snRNP biogenesis pathway is unclear. Several lines of evi-
dence suggest that the methyltransferase protein arginine 
methyltransferase 5 (PRMT5) is responsible for sDMA 
modiﬁ   cation of Sm proteins. We found that in human 
cells, PRMT5 and a newly discovered type II methyltrans-
ferase, PRMT7, are each required for Sm protein sDMA 
modiﬁ  cation. Furthermore, we show that the two enzymes 
function nonredundantly in Sm protein methylation. Lastly, 
we provide in vivo evidence demonstrating that Sm pro-
tein sDMA modiﬁ  cation is required for snRNP biogenesis 
in human cells.
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defect in snRNP levels despite expressing Sm proteins that were 
not recognized by two sDMA-specifi  c antibodies, SYM10 and 
Y12 (Gonsalvez et al., 2006). To gain a better understanding of 
the role of Sm protein sDMA modifi  cation in snRNP biogenesis 
in humans, we depleted HeLa cells of PRMT5 or PRMT7 using 
RNAi. Surprisingly, we found that both PRMT5 and PRMT7 
were required for effi   cient Sm protein sDMA modifi  cation. 
Both enzymes independently associated with Sm proteins but 
not with each other. In addition, we demonstrate that PRMT5 
and PRMT7 do not function in an additive or redundant manner, 
thus suggesting a unique requirement for each methyltransferase 
in the Sm protein methylation pathway. Finally, we show that 
the symmetric dimethylation of Sm proteins is required for 
cyto  plasmic snRNP assembly in human cells.
Results and discussion
PRMT5 and PRMT7 are required for 
Sm protein symmetric dimethylation
To understand the specifi  c requirement for Sm protein sDMA 
modifi  cation in mammals, we examined the in vivo functions of 
PRMT5, MEP50, and PRMT7. HeLa cells were depleted of these 
proteins using RNAi (Fig. 1, A and B). siRNAs targeting SMN 
or GFP were used as controls (Fig. 1, A and B). The siRNAs 
directed against PRMT5, PRMT7, and SMN were able to deplete 
>80% of their respective target proteins (Fig. 1 B). Treatment 
of cells with siRNAs targeting MEP50, a PRMT5 complex 
member, caused a slight codepletion of PRMT5 (Fig. 1 A). This 
fi  nding is consistent with our previous results in Drosophila 
 melanogaster: the mutation of valois resulted in a loss of Dart5 
expression (Gonsalvez et al., 2006). In contrast, only specifi  c 
siRNA treatments reduced the level of PRMT7 (Fig. 1 A).
We next analyzed the methylation status of Sm proteins 
in the depleted lysates using the sDMA-specifi  c antibodies 
SYM10, SYM11, and Y12 (Fig. 2 A). Unmodifi  ed and asym-
metrically dimethylated Sm proteins are not recognized by these 
antibodies (Brahms et al., 2000; Boisvert et al., 2002, 2003). 
Consistent with previous fi  ndings (Boisvert et al., 2002), the 
knockdown of PRMT5 resulted in a reduction in Sm protein 
sDMA modifi  cation (Fig. 2 A, lane 2). A similar effect was also 
observed when cells were treated with siRNAs targeting MEP50 
(Fig. 2 A, lane 4). However, because MEP50 RNAi treatment 
codepletes PRMT5, we cannot conclude whether this defect in 
methylation is direct. Curiously, we found that PRMT7 knock-
down also caused a reduction in Sm protein sDMA modifi  cation 
(Fig. 2 A, lane 3). Because the depletion of PRMT7 does not 
codeplete PRMT5 (Fig. 1 A), this effect is likely to be direct.
In addition to Sm proteins, SYM10 and SYM11 also 
recognize several uncharacterized sDMA-modifi  ed proteins 
(Boisvert et al., 2002, 2003). The same SYM10- and SYM11-
reactive proteins were hypomethylated in the PRMT5 and 
MEP50 siRNA–treated lysates (Fig. 2 A). This fi  nding was 
expected because PRMT5 and MEP50 are part of the same 
complex and also because the depletion of MEP50 codepletes 
PRMT5. In contrast, PRMT7 siRNA treatment resulted in the 
hypomethylation of only a subset of these proteins (Fig. 2 A). 
Thus, PRMT5 and PRMT7 do not always act on the same 
substrates in vivo. Consistently, we observed that the protein–
protein interaction profi  le of PRMT5 and PRMT7 was largely 
nonoverlapping (Fig. S1, available at http://www.jcb.org/cgi/
content/full/jcb.200702147/DC1).
We next determined whether Sm proteins were sDMA 
modifi  ed in an additive manner by depleting cells of both 
PRMT5 and PRMT7 (Fig. 2 B). Interestingly, double depletion 
did not disrupt Sm protein sDMA modifi  cation to a greater 
  extent than either single depletion alone. Thus, the two enzymes 
do not function additively to produce the full complement of 
methylated Sm proteins. We also attempted to determine 
whether PRMT5 and PRMT7 could functionally compensate 
for each other with respect to Sm protein sDMA modifi  cation 
(Fig. 2 C). We found that the overexpression of PRMT7 was not 
able to restore sDMA modifi  cation of the Sm protein in cells 
that were depleted of PRMT5. Thus, PRMT7 cannot function-
ally substitute for PRMT5. At this time, however, we cannot 
conclude whether the converse is also true. Although cells de-
pleted of PRMT7 alone show relatively little cytotoxicity, they 
do not survive the subsequent DNA transfection procedure. 
Transfection of PRMT7 siRNA–treated cells with empty vector 
or a PRMT5-expressing plasmid resulted in rapid and pro-
nounced cell death.
Figure 1.  siRNA treatment of PRMT5, PRMT7, MEP50, and SMN. (A) HeLa 
cells were transfected with siRNAs targeting PRMT5 (lane 2), PRMT7 (lane 3), 
MEP50 (lane 4), and SMN (lane 5). As a control, cells were untrans-
fected (mock; lane 1) or transfected with siRNAs against GFP (lane 6). 72 h 
after transfection, lysates were prepared and probed with the indicated 
antibodies. (B) The protein levels from three separate experiments were 
quantiﬁ  ed. The protein levels were normalized to tubulin and graphed as 
a fraction of the mock transfection. Error bars represent SD.POSTTRANSLATIONAL REGULATION OF SNRNP ASSEMBLY • GONSALVEZ ET AL. 735
PRMT5 has been shown to associate with the C-terminal 
arginine-glycine (RG)–rich tail of SmD3 (Friesen et al., 2001b; 
Meister et al., 2001; Meister and Fischer, 2002). Therefore, we 
tested for a similar association between SmD3 and PRMT7. We 
found that the GST-tagged C terminus of SmD3 (GST-D3tail) 
was able to specifi  cally purify both PRMT5 and PRMT7 from 
cell lysates (Fig. 2 D). Interestingly, the association between 
PRMT7 and GST-D3tail was unaffected by prior treatment of 
the cells with the methyltransferase inhibitor 5′-deoxy-5′-
(methylthio)adenosine (MTA; Fig. 2 D). In contrast, a similar 
treatment disrupted the association between PRMT5 and GST-
D3tail (Fig. 2 D). In addition to GST-D3tail, PRMT7 is able to 
bind to full-length GST-SmD3 and -SmB (unpublished data). 
Because PRMT7 is able to associate with Sm proteins but not 
Figure 2.  PRMT5 and PRMT7 are required for sDMA modiﬁ  cation of Sm proteins. (A) Lysates from mock-treated (lane 1) and PRMT5 (lane 2), PRMT7 (lane 3), 
MEP50 (lane 4), and SMN (lane 5) siRNA–treated cells were probed with anti-sDMA antibodies SYM10 (top), Y12 (middle), and SYM11 (bottom right). 
The lysates were probed with tubulin to verify load (bottom left). The open circles represent proteins that require PRMT5, MEP50, and PRMT7 for their methyl-
ation. The closed circles represent proteins that require PRMT5 and MEP50 but not PRMT7 for their methylation. The star represents a protein whose methyl-
ation status appears unaffected upon the depletion of PRMT5, MEP50, or PRMT7. (B) HeLa cells were treated with siRNAs against PRMT5 (lane 2), PRMT7 
(lane 3), or both (lane 4). GFP siRNAs were used as a control (lanes 1–3). Lysates were prepared and analyzed by blotting with the indicated antibodies. 
(C) HeLa cells were depleted of PRMT5 (lanes 2 and 3). GFP siRNAs were used as a control (lane 1). A FLAG-PRMT7 overexpression construct was trans-
fected into PRMT5-depleted cells (lane 3). Empty vector was transfected as a control (lanes 1 and 2). Lysates were prepared and analyzed by blotting with 
the indicated antibodies. The asterisk represents a protein that cross reacts with the PRMT7 antibody. (D) 1 μg GST (lanes 1 and 2) or GST-SmD3 C-terminal tail 
(GST-D3tail; lanes 3 and 4) immobilized on glutathione–Sepharose beads was incubated for 1 h with total HeLa lysates from untreated cells (lanes 1 and 3) 
or cells treated with MTA (750 μM for 24 h; lanes 2 and 4). The bound proteins were eluted by boiling in SDS buffer and analyzed by blotting using the 
indicated antibodies.JCB • VOLUME 178 • NUMBER 5 • 2007  736
with PRMT5 (Lee et al., 2005), these observations suggest a 
  direct role for PRMT7 in Sm protein methylation.
Cytoplasmic snRNP assembly requires 
the activities of both PRMT5 and PRMT7
During the cytoplasmic phase of snRNP biogenesis, the SMN 
complex loads Sm proteins onto the Sm sites of snRNAs (Meister 
et al., 2002; Paushkin et al., 2002). SMN has a much higher 
affi  nity for sDMA-modifi  ed Sm proteins in comparison with 
unmodifi  ed or aDMA-modifi  ed Sm proteins (Brahms et al., 
2001; Friesen et al., 2001a). Consistent with the fi  nding that 
both enzymes are required for the sDMA modifi  cation of Sm 
proteins, both siRNA treatments interfered with the SMN–Sm 
interaction (Fig. 3 A). Previous studies demonstrated that the 
SMN–Sm interaction was disrupted by treatment with general 
methyltransferase inhibitors (Brahms et al., 2001; Friesen et al., 
2001a). Our current results extend these fi  ndings and demon-
strate that the specifi  c depletion of either PRMT5 or PRMT7 is 
able to mimic the drug treatment.
To determine whether the methylation of Sm proteins is 
a prerequisite for effi  cient snRNP assembly, we treated HeLa 
cells with MTA. Subsequently, a pulse-chase experiment using a 
mixture of [
35S]methionine and [
35S]cysteine was used to examine 
the in vivo kinetics of snRNP assembly. The newly assembled 
  snRNPs were immunoprecipitated using anti-trimethylguanosine 
(TMG)–coated beads. Anti-TMG antibodies recognize the cap 
structure present on mature Sm-class snRNPs. More precisely, 
this assay monitors the step in snRNP biogenesis that is immedi-
ately downstream of Sm core assembly (Matera et al., 2007). 
Interestingly, we found that MTA treatment substantially dis-
rupted snRNP assembly (Fig. 3 B), suggesting that methylation is 
required for effi  cient snRNP biogenesis. Because MTA treatment 
reduced but did not completely abolish Sm protein sDMA modi-
fi  cation (Fig. S2, available at http://www.jcb.org/cgi/content/full/
jcb.200702147/DC1), we conclude that the residual snRNPs as-
sembled under these conditions contain methylated Sm proteins. 
To specifi  cally narrow down the snRNP assembly defect to 
sDMA modifi  cation of Sm proteins, HeLa cells depleted of 
Figure 3. sDMA  modiﬁ  cation of Sm proteins is re-
quired for efﬁ  cient snRNP biogenesis. (A) HeLa cells 
stably expressing CFP-SmB were depleted of PRMT5 
(lane 3) or PRMT7 (lane 4) using RNAi. Mock-treated 
cells were used as a control (lanes 1 and 2). 72 h after 
transfection, the cells were harvested, cytoplasmic 
fractions were prepared, and CFP-SmB was immuno-
precipitated using polyclonal GFP antibodies (lanes 
2–4). To verify binding speciﬁ  city, a control myc anti-
body was used (lane 1). The level of coprecipitating 
SMN was examined (top). The immunoprecipitation 
efﬁ  ciency was veriﬁ  ed using a monoclonal GFP anti-
body (bottom). (B) Cells treated for 24 h with either 
750 μM MTA (lane 3) or DMSO (lanes 1 and 2) were 
pulse labeled with [
35S]methionine and [
35S]cysteine 
for 1 h. Subsequently, complete media was added to 
the cells for a 30-min chase. The cells were harvested, 
and snRNPs were immunoprecipitated using anti-TMG 
antibody–coated beads (lanes 2 and 3). Protein A 
beads were used to demonstrate binding speciﬁ  city 
(lane 1). Representative samples were also probed 
with the tubulin antibody (bottom) to serve as a load-
ing control. The abundant copurifying U1 snRNP 
  proteins are indicated. (C) Cells depleted of SMN 
(lane 3), PRMT5 (lane 4), or PRMT7 (lane 5) were used 
in the pulse-chase assay described in A using similar 
controls. (D) The precipitated levels of the abundant 
snRNP proteins from three separate RNAi/snRNP as-
sembly experiments were quantiﬁ  ed and graphed as 
a fraction of the mock transfection. Error bars repre-
sent SD. (E) HeLa cells stably expressing CFP-SmB were 
depleted of SMN (lane 3), PRMT5 (lane 4), or PRMT7 
(lane 5). Mock-treated cells were used as a control (lanes 
1 and 2). The cells were pulsed with [
32P]orthophosphate 
for 2 h. The cells were harvested, total lysates were pre-
pared, and CFP-SmB was immunoprecipitated. Protein A 
beads were used to demonstrate binding speciﬁ  city 
(lane 1). The associated snRNAs were extracted and 
examined by autoradiography.POSTTRANSLATIONAL REGULATION OF SNRNP ASSEMBLY • GONSALVEZ ET AL. 737
PRMT5 or PRMT7 were used in the pulse-chase assay. HeLa cells 
treated with siRNAs targeting SMN served as a control. Consistent 
with previous results (Shpargel and Matera, 2005; Wan et al., 2005; 
Winkler et al., 2005), the depletion of SMN severely dis-
rupted snRNP assembly (Fig. 3, C and D; and Fig. S3, available 
at http://www.jcb.org/cgi/content/full/jcb.200702147/DC1). 
Figure 4.  Coilin is found in nucleolar caps in cells depleted of SMN, PRMT5, or PRMT7. (A) Control cells as well as cells depleted of SMN, PRMT5, or PRMT7 
were processed for immunoﬂ  uoresence using antibodies against coilin (red) and ﬁ  brillarin (green). The arrows indicate the nucleolar capping phenotype. The 
images in A and B represent the maximum projection of a z stack that has been deconvolved. (B) Cells depleted of PRMT5 and PRMT7 were processed for 
  immunoﬂ  uoresence using antibodies against coilin (red) and SMN (green). PRMT7-depleted cells are shown. Note that the coilin nucleolar caps (arrows) also 
contain SMN. (C) Cells depleted of SMN, PRMT5, or PRMT7 were scored for the presence of CBs and also for the coilin nucleolar capping phenotype. The 
results were graphed as a percentage of the mock-treated cells. A total of 200 cells were scored for each treatment condition. Bars, 10 μM.JCB • VOLUME 178 • NUMBER 5 • 2007  738
A similar disruption of snRNP assembly was also observed in cells 
depleted of either PRMT5 or PRMT7 (Figs. 3, C and D; and S3). 
It is worth noting that snRNP assembly was disrupted to a some-
what lesser extent upon the depletion of either PRMT5 or PRMT7 
as compared with SMN (Fig. 3, C and D). These fi  ndings are con-
sistent with the observation that PRMT5 and PRMT7 depletion re-
duces but does not eliminate the SMN–Sm interaction (Fig. 3 A).
The most likely function for PRMT5 and PRMT7 in the 
snRNP biogenesis pathway is to enable the effi  cient association of 
SMN with Sm proteins. Therefore, we directly examined the as-
sembly of Sm cores in control or depleted lysates. For this exper-
iment, a HeLa strain stably expressing CFP-SmB (Sleeman et al., 
2001) was used. The cells were pulsed with [
32P]orthophosphate. 
Subsequently, tagged SmB was immunoprecipitated from the 
  labeled lysates. The associated RNAs were examined by auto-
radiography. As expected, the depletion of SMN considerably 
  inhibited Sm core assembly (Fig. 3 E). Likewise, the depletion of 
either PRMT5 or PRMT7 also resulted in a similar Sm core 
  assembly defect (Fig. 3 E).
Sm protein sDMA modiﬁ  cation is primarily 
required for cytoplasmic snRNP assembly
The depletion of core snRNP assembly factors results in the 
breakdown of Cajal bodies (CBs) and the redistribution of coilin 
to the nucleolus (Shpargel and Matera, 2005; Girard et al., 2006; 
Lemm et al., 2006). Therefore, we examined whether the deple-
tion of PRMT5 or PRMT7 also leads to CB breakdown (Fig. 4). 
Consistent with these earlier studies, CBs were undetected in 
 60% of SMN-depleted cells (Fig. 4 C). In contrast, roughly 
30% of cells depleted of PRMT5 or PRMT7 lacked visible CBs 
(Fig. 4 C). Also consistent with these earlier studies, coilin lo-
calized within the nucleolus in a subset of SMN-depleted cells 
(unpublished data). This phenotype was not observed in cells 
depleted of PRMT5 or PRMT7. However, in a subset of cells de-
pleted for PRMT5, PRMT7, or SMN, coilin localized at the 
  nucleolar periphery (Fig. 4, A and C). Interestingly, in cells de-
pleted of PRMT5 or PRMT7, we found that these nucleolar caps 
also contained SMN (Fig. 4 B and not depicted). Thus, in con-
trast to SMN depletion, PRMT5 or PRMT7 depletion produced 
a milder CB phenotype. One explanation for this fi  nding is that 
SMN depletion results in a more severe snRNP defect than ei-
ther methyltransferase deletion (Fig. 3 D). Alternatively, in con-
trast to PRMT5 and PRMT7, SMN may play additional roles in 
targeting imported snRNPs to CBs (Ospina et al. 2005).
Finally, we tested whether Sm protein methylation was 
  required for snRNP import using the 
35S pulse-chase assay. 
 Labeled cells were harvested, and nuclear and cytoplasmic fractions 
were prepared. Each fraction was then subjected to immuno-
precipitation using anti-TMG antibody–coated beads. TMG-
positive RNPs produced during the 1.5-h pulse-chase period were 
nearly all located in the nuclear fraction (Fig. 5 A), suggesting 
that in HeLa cells, snRNP biogenesis and nuclear import occur 
relatively rapidly. As observed previously (Fig. 3 A), MTA treat-
ment disrupted snRNP assembly. However, the residual snRNPs 
that were assembled were present almost exclusively in the 
  nuclear fraction (Fig. 5 A). Similar to MTA treatment, RNAi-
mediated depletion of SMN, PRMT5, or PRMT7 resulted in 
  snRNP assembly defects (Fig. 5 B). As with MTA treatment, the 
residual snRNPs that were assembled were also imported into 
the nucleus (Fig. 5 B). Thus, sDMA modifi  cation of Sm proteins 
does not play a major role in the nuclear import of snRNPs.
During the preparation of this manuscript, PRMT9 was 
shown to possess type II methyltransferase activity and to methyl-
ate a variety of targets in vitro, including SmB (Cook et al., 
2006). Therefore, it will be interesting to determine whether 
PRMT9 plays a role in Sm protein methylation and snRNP bio-
genesis in vivo. In addition, CARM1/PRMT4, a type I methyl-
transferase, was recently shown to asymmetrically dimethylate 
SmB in vivo (Cheng et al., 2007). Because aDMA residues are 
found exclusively on nuclear Sm proteins (Miranda et al., 2004), 
this modifi  cation is not likely to be required for the cytoplasmic 
phase of snRNP assembly. The aDMA modifi  cation of Sm pro-
teins may be important for subnuclear targeting of snRNPs or 
for the regulation of pre-mRNA splicing (Cheng et al., 2007).
In conclusion, we have shown that two distinct methyl-
transferases, PRMT5 and PRMT7, are required for Sm protein 
sDMA modifi  cation and snRNP assembly. We envision that both 
enzymes function in the snRNP pathway by sDMA modifi  cation 
Figure 5.  PRMT5, PRMT7, and SMN deple-
tion affects cytoplasmic snRNP assembly. 
(A) Cells treated for 24 h with either 750 μM 
MTA (lanes 2 and 4) or DMSO (lanes 1 and 3) 
were pulse labeled with 
35S as described in 
Fig. 3 A. The cells were harvested, and nuclear 
and cytoplasmic fractions were prepared. The 
snRNPs from each fraction were immunoprecip-
itated using anti-TMG antibody–coated beads. 
(B) Cells depleted of SMN (lanes 2 and 6), 
PRMT5 (lanes 3 and 7), or PRMT7 (lanes 4 
and 8) were used in the pulse-chase assay. 
Mock-treated cells were used as a control 
(lanes 1 and 5). Binding conditions are the same 
as in A.POSTTRANSLATIONAL REGULATION OF SNRNP ASSEMBLY • GONSALVEZ ET AL. 739
of Sm proteins, thus increasing their affi  nity for the SMN 
complex. A previous study showed that the activity of the SMN 
complex in Sm core assembly is stimulated by phosphorylation 
(Grimmler et al., 2005). Here, we demonstrate that sDMA modi-
fi  cation of Sm proteins also serves an important regulatory func-
tion. Thus, mammalian snRNP biogenesis is controlled by 
multiple posttranslational events. Drosophila may differ from 
mammals in this regard. Whereas PRMT5 is required for snRNP 
biogenesis in human cells, the loss of Dart5 does not result in de-
creased snRNP levels in Drosophila. However, fl  ies also express 
an orthologue of PRMT7 called Dart7. Therefore, it will be inter-
esting to test whether snRNP assembly in Drosophila is indepen-
dent of Sm protein sDMA modifi  cation.
Materials and methods
DNA/siRNA constructs
GST-tagged SmD3 C-terminal tail (GST-D3tail) was a gift from G. Dreyfuss 
(University of Pennsylvania, Philadelphia, PA). The FLAG-PRMT7 over-
expression plasmid was constructed by cloning PRMT7 cDNA into the p3X-
FLAG-myc-CMV-23 expression vector (Sigma-Aldrich). Because the PRMT7 
construct contains its endogenous stop codon, the C-terminal myc tag is not 
translated. The siRNAs used in these studies were obtained from Ambion. 
The PRMT5 siRNA sequence is G  G  C  C  A  U  C  U  A  U  A  A  A  U  G  U  C  U  G  , and the 
PRMT7 siRNA sequence is G  C  U  A  U  U  U  C  C  C  A  U  C  C  A  C  G  U  G  .
Cell culture and transfections
HeLa cells were cultured in DME supplemented with 10% FBS. For each 
RNAi transfection, 275 pmol siRNAs were transfected into a 20% conﬂ  uent 
T25 ﬂ  ask using the DharmaFECT1 reagent (Dharmacon). For those experi-
ments in which the steady-state methylation status of the Sm proteins was 
analyzed (Fig. 2, A–C), the cells were treated with siRNA twice—once on 
day 1 and once on day 3. The cells were harvested and analyzed on day 5. 
This was done to accommodate the long half-life of Sm proteins. For the 
rest of the RNAi experiments, the cells were treated with siRNA just once. 
The cells were harvested and analyzed on day 3. DNA was transfected 
  using Effectene (QIAGEN).
Lysate preparation
HeLa lysates were prepared by resuspending the cells in radioimmuno-
precipitation assay buffer (50 mM Tris-Cl, pH 7.5, 150 mM NaCl, 1% NP-40, 
and 1 mM EDTA) containing protease inhibitors (Halt protease inhibitor 
cocktail kit; Pierce Chemical Co.) and passing several times through a 
25-gauge needle. The lysate was cleared by centrifugation at 10,000 g for 
5 min at 4°C. Nuclear and cytoplasmic HeLa fractions were prepared using 
the N-PER fractionation kit (Pierce Chemical Co.) as directed. Bacterial ly-
sates were prepared using sonication in 1× PBS/1% Triton X-100/protease 
inhibitor cocktail.
Antibodies, immunoprecipitations, and immunoﬂ  uorescence
The PRMT5 and PRMT7 antibodies were obtained from Upstate Biotechnol-
ogy. The SMN antibody (clone 7B10) was a gift from U. Fischer (University 
of Wuerzburg, Wuerzburg, Germany). The tubulin monoclonal antibody 
used as a loading control was obtained from Sigma-Aldrich. The methyl-
ation status of the depleted lysates was analyzed using Sym10 (Upstate 
  Biotechnology), Sym11 (Upstate Biotechnology), and Y12 anti-sDMA anti-
bodies (gift from J. Steitz, Yale, New Haven, CT). CFP-SmB was immuno-
precipitated from cytoplasmic lysates using polyclonal GFP antibodies 
(Abcam). The precipitates were probed using SMN and GFP monoclonal 
antibodies (Roche). In the pulse-chase experiments, the newly synthesized 
snRNPs were precipitated using anti-TMG antibody–coated beads (Calbio-
chem). For the Sm core assembly assay, CFP-SmB was immunoprecipitated 
using the polyclonal GFP antibody. The distribution of coilin was examined 
using a previously generated polyclonal antibody R124 (Shpargel and 
Matera, 2005) and a goat anti–rabbit AlexaFluor594 secondary antibody 
(Jackson ImmunoResearch Laboratories). The localization of ﬁ  brillarin was 
determined using the 72b9 antibody (gift from E. Chan, University of 
  Florida, Gainesville, FL), and the distribution of SMN was veriﬁ  ed using the 
7B10 monoclonal antibody. A goat anti–mouse FITC antibody (Jackson 
  ImmunoResearch Laboratories) was used to detect ﬁ   brillarin and SMN. 
Western blots and autoradiography ﬁ  lm were quantiﬁ  ed using the Quantity 
One program (Bio-Rad Laboratories).
Imaging
Immunoﬂ  uorescence images were captured using a microscope (DM6000; 
Leica) interfaced with Volocity software (Improvision). Images were cap-
tured at room temperature using a 63× oil immersion objective (Leica). The 
image stacks were deconvolved using Volocity software. Images were 
cropped using Photoshop 7.0 (Adobe).
Pulse-chase assays
The [
35S]methionine and [
35S]cysteine pulse-chase assay was performed as 
described previously (Winkler et al., 2005) with a few modiﬁ  cations. The 
chase time was reduced from 1 h to 30 min. The newly synthesized snRNPs 
were puriﬁ  ed using anti-TMG antibody–coated beads. Cells were treated 
with 750 μM MTA for 24 h. An equivalent volume of DMSO was added 
to the control cells. In the snRNP import experiment, nuclear and cytoplas-
mic fractions were prepared subsequent to the pulse chase using the N-PER 
kit (Pierce Chemical Co.). Subsequently, each fraction was incubated with 
anti-TMG–coated beads. The 
32P-labeling experiment was performed by 
ﬁ  rst depleting cells of intracellular phosphate by growing in 3 ml phos-
phate-free DME media for 2 h. Subsequently, 100 μCi [
32P]orthophosphate 
(PerkinElmer) was added to the cells. The cells were labeled for 2 h and 
harvested. For the Sm core assembly reaction, HeLa cells stably expressing 
CFP-SmB were used. The tagged Sm protein was immunoprecipitated using 
polyclonal GFP antibodies. The associated snRNAs were then examined 
using autoradiography. The 
32P-labeled cells were also used in a separate 
TMG-capping assay. The TMG-capped snRNPs were puriﬁ   ed using the 
anti-TMG antibody–coated beads. The RNA was extracted and examined 
using autoradiography.
Online supplemental material
Fig. S1 shows that PRMT5 and PRMT7 associate with different proteins 
in vivo. Fig. S2 shows that residual snRNPs assembled under condi-
tions of MTA treatment contain symmetrically dimethylated Sm proteins. 
Fig. S3 shows that SMN, PRMT5, and PRMT7 are required for TMG capping. 
Online supplemental material is available at http://www.jcb.org/cgi/
content/full/jcb.200702147/DC1.
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